Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:51:52.605Z.
Calculation as of: 2026-10-06T19:51:52.605Z.
Quote observation: 2026-10-06T19:50:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2576380beaab4b3cbce085b4235445012990db653f345db98d0cfe80ba67c11f
PE RATIO
N/A
Market Cap
$52.60M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | $50.44M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $51.55M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.98M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.12M | N/A | N/A | N/A | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | N/A | N/A | N/A | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $50.66M | N/A | 1.95 | 1.95 | 1.95 |
| Spectral AI, Inc. (MDAI)vs › | $52.99M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $53.71M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.59M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $50.31M | N/A | 13.56 | 13.56 | 13.56 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.50
Forward EPS (Est.)
$-0.87
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
